INSP Intrinsic Value – INSPIRE MEDICAL SYSTEMS Reports Q2 FY2023 Earnings Results on June 30, 2023
August 15, 2023
☀️Earnings Overview
On June 30th 2023, INSPIRE MEDICAL SYSTEMS ($NYSE:INSP) released their financial results for the second quarter of their 2023 fiscal year. Revenue totalled USD 151.1 million, a significant 65.3% increase compared to the same quarter of the previous year. Additionally, their net income was USD -12.0 million, representing an improvement from the -14.5 million reported the year before.
Market Price
On Tuesday, June 30, 2023, INSPIRE MEDICAL SYSTEMS released their financial results for the second quarter of the fiscal year 2023. The opening stock price for the day was $285.0, and by the end of trading it had increased to $290.9, representing a 1.1% increase from the previous close of $287.8. The quarterly earnings report revealed that the company had experienced strong growth in both sales and profits compared to the same period last year. This was attributed to a combination of rising demand for their products, as well as cost-saving measures taken throughout the quarter.
Following the release of the results, INSPIRE MEDICAL SYSTEMS’ stock price rose further, reflecting the strong performance. The company’s board of directors noted that they were pleased with the results and were optimistic for the rest of the fiscal year. They reiterated their commitment to continue to invest in new products, services, and research to further strengthen their position in the market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for INSP. More…
| Total Revenues | Net Income | Net Margin |
| 526.08 | -41.07 | -7.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for INSP. More…
| Operations | Investing | Financing |
| 34.02 | -5.57 | 251.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for INSP. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 618.25 | 88.89 | 18.05 |
Key Ratios Snapshot
Some of the financial key ratios for INSP are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 86.3% | – | -7.5% |
| FCF Margin | ROE | ROA |
| 3.6% | -4.8% | -4.0% |
Analysis – INSP Intrinsic Value
We at GoodWhale have conducted an analysis of INSPIRE MEDICAL SYSTEMS’s wellbeing and come to the conclusion that its fair value is around $443.5. This has been calculated using our proprietary Valuation Line. At the moment, INSPIRE MEDICAL SYSTEMS stock is traded at $290.9, which is 34.4% undervalued. This presents investors with an opportunity to invest in a company with a good track record at a discounted price. More…
Peers
The company’s competitors include ShockWave Medical Inc, InMode Ltd, and INVO Bioscience Inc.
– ShockWave Medical Inc ($NASDAQ:SWAV)
ShockWave Medical Inc is a medical device company that uses shockwave technology to treat cardiovascular disease. The company has a market cap of 9.73B as of 2022 and a return on equity of 19.56%. The company’s products are used to treat a variety of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and heart failure.
– InMode Ltd ($NASDAQ:INMD)
InMode Ltd is a medical technology company that develops and manufactures minimally invasive aesthetic solutions. The company has a market capitalization of $2.71 billion as of 2022 and a return on equity of 41.58%. InMode’s products are used by physicians and patients in over 90 countries and the company has a strong presence in the United States, Europe, Asia, and Latin America. InMode’s products are backed by clinical research and have been featured in numerous peer-reviewed journals.
– INVO Bioscience Inc ($NASDAQ:INVO)
INVO Bioscience Inc is a medical device company that has developed a patented in vivo intravaginal culture (IVC) system, which is used to treat infertility. The company’s IVC system is designed to provide a more natural environment for embryo development and is intended to improve the success rates of in vitro fertilization (IVF). INVO Bioscience’s IVC system is currently being used at fertility clinics in the United States and Europe.
Summary
Investors in Inspire Medical Systems should be encouraged by its recently reported second quarter financials. Total revenue for the quarter increased by 65.3% year-on-year to USD 151.1 million, resulting in a net income for the quarter of -12.0 million, significantly better than the -14.5 million reported in the same period a year prior. With this strong performance, Inspire Medical Systems continues to show signs of future growth potential, making it an attractive option for investors looking for a long-term return on their investment.
Related Posts
Recent Posts
